Akebia Therapeutics (NASDAQ: AKBA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Akebia Therapeutics reported 16 open-market sales of 704,058 shares ($962,955) and 1 open-market purchase of 69,270 shares ($86,588), by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Akebia Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
6 August 2026	Butler John P.	CEO and President	Option exercise	+350,000	$0.63	3,718,564	Form 4
29 June 2026	Ostrowski Erik	SVP, CFO, CBO & Treasurer	Open-market sale	−56,019	$1.11	616,616	Form 4
17 June 2026	Zumwalt Leanne M	Director	Grant or award	+35,700	—	145,100	Form 4
17 June 2026	Rogers Michael W	Director	Grant or award	+35,700	—	197,429	Form 4
17 June 2026	Adams Adrian	Director	Grant or award	+35,700	—	236,200	Form 4
17 June 2026	Smith Cynthia	Director	Grant or award	+35,700	—	196,633	Form 4
17 June 2026	Wolf Myles	Director	Grant or award	+35,700	—	169,081	Form 4
17 June 2026	Frieson Ron	Director	Grant or award	+35,700	—	165,200	Form 4
4 March 2026	Butler John P.	CEO and President	Open-market purchase	+69,270	$1.25	3,367,064	Form 4
2 February 2026	Butler John P.	CEO and President	Open-market sale	−46,660	$1.39	3,417,189	Form 4
2 February 2026	Butler John P.	CEO and President	Open-market sale	−96,065	$1.39	3,321,124	Form 4
2 February 2026	Butler John P.	CEO and President	Open-market sale	−114,891	$1.39	3,206,233	Form 4
2 February 2026	Butler John P.	CEO and President	Grant or award	+175,250	$1.41	3,381,483	Form 4
2 February 2026	Butler John P.	CEO and President	Open-market sale	−83,689	$1.39	3,297,794	Form 4
2 February 2026	Burke Steven Keith	SVP, Chief Medical Officer	Open-market sale	−21,582	$1.39	994,508	Form 4
2 February 2026	Burke Steven Keith	SVP, Chief Medical Officer	Open-market sale	−25,375	$1.39	969,133	Form 4
2 February 2026	Burke Steven Keith	SVP, Chief Medical Officer	Open-market sale	−20,701	$1.39	948,432	Form 4
2 February 2026	Grund Nicholas	Chief Commercial Officer	Open-market sale	−53,585	$1.39	592,994	Form 4
2 February 2026	Grund Nicholas	Chief Commercial Officer	Open-market sale	−31,244	$1.39	561,750	Form 4
2 February 2026	Ostrowski Erik	SVP, CFO, CBO & Treasurer	Open-market sale	−34,951	$1.39	672,635	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Akebia Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.